ID   SK-MEL-147
AC   CVCL_3876
SY   SK-Mel-147; SK MEL 147; SKMEL-147; SkMel147; SKMEL147; SK-147; FT-Mel
DR   cancercelllines; CVCL_3876
DR   ChEMBL-Cells; CHEMBL4630606
DR   ChEMBL-Targets; CHEMBL4630706
DR   Cosmic; 685208
DR   Cosmic; 721808
DR   Cosmic; 933133
DR   Cosmic; 1054851
DR   Cosmic; 1122259
DR   Cosmic; 1247853
DR   Cosmic; 1507623
DR   Cosmic; 1669174
DR   Cosmic; 2233673
DR   GEO; GSM555128
DR   GEO; GSM555181
DR   GEO; GSM1507943
DR   GEO; GSM5466407
DR   GEO; GSM5466408
DR   GEO; GSM5466409
DR   Lonza; 1338
DR   Millipore; SCC440
DR   PRIDE; PXD007000
DR   Progenetix; CVCL_3876
DR   PubChem_Cell_line; CVCL_3876
DR   Wikidata; Q54953834
RX   PubMed=1716514;
RX   PubMed=6864164;
RX   PubMed=7747814;
RX   PubMed=9598804;
RX   PubMed=17308088;
RX   PubMed=18505964;
RX   PubMed=21343389;
RX   PubMed=21725359;
RX   PubMed=24576830;
RX   PubMed=25502142;
RX   PubMed=25728708;
CC   From: Memorial Sloan Kettering Cancer Center; New York; USA.
CC   Sequence variation: Gene deletion; HGNC; HGNC:1788; CDKN2B; Zygosity=Homozygous (PubMed=9598804).
CC   Sequence variation: Mutation; HGNC; HGNC:1787; CDKN2A; Simple; p.Pro114Leu (c.341C>T) (p.Ala128Ala, c.384C>T); ClinVar=VCV000077637; Zygosity=Unspecified (PubMed=9598804; PubMed=7747814).
CC   Sequence variation: Mutation; HGNC; HGNC:7989; NRAS; Simple; p.Gln61Arg (c.182A>G); ClinVar=VCV000013900; Zygosity=Unspecified (PubMed=21725359; PubMed=24576830; PubMed=25728708).
CC   Omics: Transcriptomics; Microarray.
CC   Omics: Transcriptomics; RNAseq.
CC   Omics: Variations; SNP array analysis.
CC   Derived from site: Metastatic; Not specified.
ST   Source(s): Millipore=SCC440
ST   Amelogenin: X
ST   CSF1PO: 10,12
ST   D13S317: 9,11
ST   D16S539: 12,13
ST   D18S51: 13,17
ST   D21S11: 30,31
ST   D3S1358: 17,18
ST   D5S818: 10,13
ST   D7S820: 9,11
ST   D8S1179: 12,17
ST   FGA: 21,24
ST   Penta D: 9,12
ST   Penta E: 12,13
ST   TH01: 6,9.3
ST   TPOX: 8,12
ST   vWA: 17,18
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
SX   Sex unspecified
AG   Age unspecified
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 14-08-25; Version: 30
//
RX   PubMed=25502142; DOI=10.1038/ncomms6712; PMCID=PMC4428333;
RA   Muller, Judith
RA   Krijgsman, Oscar
RA   Tsoi, Jennifer
RA   Robert, Lidia
RA   Hugo, Willy
RA   Song, Chunying
RA   Kong, Xiang-Ju
RA   Possik, Patricia Abrao
RA   Cornelissen-Steijger, Paulien D.M.
RA   Geukes Foppen, Marnix H.
RA   Kemper, Kristel
RA   Goding, Colin Ronald
RA   McDermott, Ultan
RA   Blank, Christian
RA   Haanen, John
RA   Graeber, Thomas G.
RA   Ribas, Antoni
RA   Lo, Roger S.
RA   Peeper, Daniel S.
RT   "Low MITF/AXL ratio predicts early resistance to multiple targeted
RT   drugs in melanoma.";
RL   Nat. Commun. 5:5712.1-5712.15(2014).
//
RX   PubMed=1716514;
RA   Albino, Anthony P.
RA   Davis, Brigid M.
RA   Nanus, David Michael
RT   "Induction of growth factor RNA expression in human malignant
RT   melanoma: markers of transformation.";
RL   Cancer Res. 51:4815-4820(1991).
//
RX   PubMed=17308088; DOI=10.1158/0008-5472.CAN-06-3311;
RA   Shields, Janiel M.
RA   Thomas, Nancy E.
RA   Cregger, Melissa
RA   Berger, Aaron J.
RA   Leslie, Michael
RA   Torrice, Chad
RA   Hao, Hong-Lin
RA   Penland, Shannon
RA   Arbiser, Jack Leonard
RA   Scott, Glynis A.
RA   Zhou, Tong
RA   Bar-Eli, Menashe
RA   Bear, James E.
RA   Der, Channing Joseph
RA   Kaufmann, William K.
RA   Rimm, David Laurence
RA   Sharpless, Norman Edward
RT   "Lack of extracellular signal-regulated kinase mitogen-activated
RT   protein kinase signaling shows a new type of melanoma.";
RL   Cancer Res. 67:1502-1512(2007).
//
RX   PubMed=9598804; DOI=10.1002/(SICI)1098-2264(199806)22:2<157::AID-GCC11>3.0.CO;2-N;
RA   Walker, Graeme J.
RA   Flores, Jose F.
RA   Glendening, J. Michael
RA   Lin, Amy Hsiu-Ti
RA   Markl, Isabel D.C.
RA   Fountain, Jane W.
RT   "Virtually 100% of melanoma cell lines harbor alterations at the DNA
RT   level within CDKN2A, CDKN2B, or one of their downstream targets.";
RL   Genes Chromosomes Cancer 22:157-163(1998).
//
RX   PubMed=25728708; DOI=10.1111/pcmr.12364;
RA   Vogel, Celia J.
RA   Smit, Marjon A.
RA   Maddalo, Gianluca
RA   Possik, Patricia Abrao
RA   Sparidans, Rolf W.
RA   van der Burg, Sjoerd Henricus
RA   Verdegaal, Elizabeth M.E.
RA   Heck, Albert J.R.
RA   Samatar, Ahmed A.
RA   Beijnen, Jos Heindrik
RA   Altelaar, A.F. Maarten
RA   Peeper, Daniel S.
RT   "Cooperative induction of apoptosis in NRAS mutant melanoma by
RT   inhibition of MEK and ROCK.";
RL   Pigment Cell Melanoma Res. 28:307-317(2015).
//
RX   PubMed=21343389; DOI=10.1158/0008-5472.CAN-10-2958; PMCID=PMC3070783;
RA   Rose, Amy E.
RA   Poliseno, Laura
RA   Wang, Jin-Hua
RA   Clark, Michael
RA   Pearlman, Alexander
RA   Wang, Gui-Min
RA   Vega y Saenz de Miera, Eleazar Carmelo
RA   Medicherla, Ratna
RA   Christos, Paul J.
RA   Shapiro, Richard
RA   Pavlick, Anna
RA   Darvishian, Farbod
RA   Zavadil, Jiri
RA   Polsky, David
RA   Hernando, Eva
RA   Ostrer, Harry
RA   Osman, Iman
RT   "Integrative genomics identifies molecular alterations that challenge
RT   the linear model of melanoma progression.";
RL   Cancer Res. 71:2561-2571(2011).
//
RX   PubMed=6864164; DOI=10.1084/jem.158.1.53; PMCID=PMC2187084;
RA   Houghton, Alan N.
RA   Brooks, Hannah
RA   Cote, Richard J.
RA   Taormina, Michael C.
RA   Oettgen, Herbert Friedrich
RA   Old, Lloyd John
RT   "Detection of cell surface and intracellular antigens by human
RT   monoclonal antibodies. Hybrid cell lines derived from lymphocytes of
RT   patients with malignant melanoma.";
RL   J. Exp. Med. 158:53-65(1983).
//
RX   PubMed=24576830; DOI=10.1158/0008-5472.CAN-13-2625; PMCID=PMC4005042;
RA   Nissan, Moriah Heller
RA   Pratilas, Christine A.
RA   Jones, Alexis M.
RA   Ramirez, Ricardo
RA   Won, Helen
RA   Liu, Cai-Lian
RA   Tiwari, Shakuntala
RA   Kong, Li
RA   Hanrahan, Aphrothiti J.
RA   Yao, Zhan
RA   Merghoub, Taha
RA   Ribas, Antoni
RA   Chapman, Paul B.
RA   Yaeger, Rona D.
RA   Taylor, Barry Stephen
RA   Schultz, Nikolaus
RA   Berger, Michael F.
RA   Rosen, Neal
RA   Solit, David B.
RT   "Loss of NF1 in cutaneous melanoma is associated with RAS activation
RT   and MEK dependence.";
RL   Cancer Res. 74:2340-2350(2014).
//
RX   PubMed=21725359; DOI=10.1038/onc.2011.250; PMCID=PMC3267014;
RA   Xing, Feng
RA   Persaud, Yogindra
RA   Pratilas, Christine A.
RA   Taylor, Barry Stephen
RA   Janakiraman, Manickam
RA   She, Qing-Bai
RA   Gallardo, Humilidad F.
RA   Liu, Cai-Lian
RA   Merghoub, Taha
RA   Hefter, Blake E.
RA   Dolgalev, Igor
RA   Viale, Agnes J.
RA   Heguy, Adriana
RA   de Stanchina, Elisa
RA   Cobrinik, David
RA   Bollag, Gideon
RA   Wolchok, Jedd David
RA   Houghton, Alan N.
RA   Solit, David B.
RT   "Concurrent loss of the PTEN and RB1 tumor suppressors attenuates RAF
RT   dependence in melanomas harboring (V600E)BRAF.";
RL   Oncogene 31:446-457(2012).
//
RX   PubMed=18505964; DOI=10.1093/jnci/djn157; PMCID=PMC4410798;
RA   Freedberg, Daniel E.
RA   Rigas, Sushilaben Harkisandas
RA   Russak, Julie E.
RA   Gai, Wei-Ming
RA   Kaplow, Margarita E.
RA   Osman, Iman
RA   Turner, Faye
RA   Randerson-Moor, Juliette A.
RA   Houghton, Alan N.
RA   Busam, Klaus J.
RA   Bishop, David Timothy
RA   Bastian, Boris C.
RA   Newton-Bishop, Julia A.
RA   Polsky, David
RT   "Frequent p16-independent inactivation of p14ARF in human melanoma.";
RL   J. Natl. Cancer Inst. 100:784-795(2008).
//
RX   PubMed=7747814; PMCID=PMC1869278;
RA   Gruis, Nelleke A.
RA   Weaver-Feldhaus, Jane M.
RA   Liu, Qing-Yun
RA   Frye, Cheryl
RA   Eeles, Rosalind
RA   Orlow, Irene
RA   Lacombe, Louis
RA   Ponce-Castaneda, Veronica
RA   Lianes, Pilar
RA   Latres, Esther
RA   Skolnick, Mark Henry
RA   Cordon-Cardo, Carlos
RA   Kamb, Alexander
RT   "Genetic evidence in melanoma and bladder cancers that p16 and p53
RT   function in separate pathways of tumor suppression.";
RL   Am. J. Pathol. 146:1199-1206(1995).
//